[Predictive values of serum endocan and retinol-binding protein 4 levels for pregnancy outcomes in patients with gestational diabetes mellitus].

<b>Objective:</b> To investigate the predictive value of serum endocan and retinol-binding protein 4 (RBP4) levels for adverse pregnancy outcomes in patients with gestational diabetes mellitus (GDM). <b>Methods:</b> A total of 151 GDM patients admitted to Yantaishan Hospital from May 2021 to April 2023 were enrolled as the GDM group, with an average age of (32.9±5.3) years. Based on the occurrence of adverse pregnancy outcomes, GDM patients were further divided into the adverse pregnancy outcomes group (<i>n</i>=30) and the normal pregnancy outcomes group (<i>n</i>=121). Clinical indicators were compared between two groups. Multivariate logistic regression was used to analyze risk factors for adverse pregnancy outcomes in GDM patients. The predictive value of serum endocan and RBP4 for adverse pregnancy outcomes in patients with GDM was assessed using the area under the receiver operating characteristic curve (AUC). <b>Results:</b> The adverse pregnancy outcomes group exhibited higher endocan [(176.63±38.80) vs (151.33±37.14) ng/L] and RBP4 [(44.71±3.89) vs (37.59±3.76) mg/L] levels compared to the normal pregnancy outcomes group (both <i>P</i><0.05). Multivariate logistic regression model indicated that the elevated levels of endocan (<i>OR</i>=1.609, 95%<i>CI</i>: 1.707-4.660) and RBP4 (<i>OR</i>=1.874, 95%<i>CI</i>: 1.486-5.609) were risk factors for adverse pregnancy outcomes. The AUC for serum endocan in predicting adverse pregnancy outcomes in GDM patients was 0.742 (0.643-0.840). At a cut-off value of 162.20 ng/L, the sensitivity and specificity were 68.6% and 76.7%, respectively. The AUC for RBP4 in predicting adverse pregnancy outcomes in GDM patients was 0.845 (0.756-0.934). At a cut-off value of 41.30 mg/L, the sensitivity and specificity were 88.4% and 73.3%, respectively. When combining both markers, the AUC, sensitivity, and specificity were 0.901 (0.835-0.967), 87.6%, and 90.0%, respectively. <b>Conclusions:</b> Elevated serum endocan and RBP4 levels are associated with adverse pregnancy outcomes in GDM patients. Monitoring these biomarkers may aid in risk stratification and clinical decision-making for GDM pregnancies.